YOLFTbeta
PolTREG S.A.

PolTREG S.A.

PTG · WAR · Healthcare / Biotechnology

19.50PLN+0.20 (+1.04%)

Price History

Full chart

Market Stats

Previous Close19.30
Open19.25
Day Range18.30 – 19.50
52-Week Range16.00 – 29.80
Volume2.83K
Market Cap120.10M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.98
Dividend Yield0.00%
Beta0.82
50-Day Avg23.45
200-Day Avg22.11

About

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient's damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Piotr Trzonkowsk
  • Employees34
  • Headquartersul. Botaniczna 20, Gdansk, Poland, 80-298, Poland
  • Websitehttps://poltreg.bio

Leadership

  • Mr. Piotr TrzonkowskPresident of the Management Board
  • Ms. Paulina Kocenko-MerksCFO & Member of Management Board
  • Mr. Mariusz JablonskiMember of the Management Board
  • Ms. Kamilla Agnieszka BokDirector of Operations

Financials

Income Statement

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0500.00K700.00K1.10M999.00K1.40M350.00K0
Growth (%)--+40.00%+57.00%-9.10%+40.04%-74.98%-100.00%
Cost of Revenue105.00K278.00K243.00K282.00K1.12M2.79M4.79M5.66M
Gross Profit-105.00K222.00K457.00K817.00K-124.00K-1.39M-4.45M-5.66M
Gross Margin-44.40%65.29%74.34%-12.41%-99.14%-1270.00%-
Operating Expense1.16M902.00K1.41M4.30M5.11M15.47M15.83M29.86M
Operating Income-1.26M-680.00K-955.00K-3.48M-5.23M-16.86M-20.28M-35.52M
Operating Margin--136.00%-136.43%-316.65%-523.72%-1205.29%-5794.00%-
EBITDA-791.00K-202.00K-217.00K-3.12M-860.00K-11.66M-13.87M-29.86M
EBITDA Margin--40.40%-31.00%-284.08%-86.09%-833.38%-3961.43%-
Net Income-1.35M-967.00K-878.00K-3.74M-1.97M-13.55M-18.71M-26.00M
Net Income Margin--193.40%-125.43%-340.13%-196.90%-968.62%-5345.14%-
Interest Expense249.00K198.00K104.00K41.00K301.00K356.00K837.00K929.00K
Interest Expense % of Total Revenue-39.60%14.86%3.73%30.13%25.45%239.14%-

Balance Sheet

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.46M6.84M16.24M109.13M123.31M127.10M102.38M72.96M
Total Liabilities9.70M6.85M3.41M6.12M22.27M39.58M33.15M17.19M
Total Equity764.00K-6.00K12.83M103.01M101.04M87.52M69.23M43.33M
Cash7.91M5.17M15.05M103.94M90.04M65.95M45.66M17.79M
Total Debt4.07M2.04M763.00K178.00K7.90M8.19M7.97M7.62M
Net Debt-3.83M-3.13M-14.29M-103.76M-82.14M-57.76M-37.69M-10.16M

Cash Flow

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.04M-1.19M-2.79M-3.84M-8.60M-13.28M-16.00M-28.68M
Investing Cash Flow4.72M417.00K362.00K-454.00K-5.05M-31.57M-8.75M-547.00K
Financing Cash Flow-47.00K-1.96M12.30M93.18M2.28M20.77M4.46M1.35M
Capital Expenditure103.00K421.00K2.97M2.97M7.58M31.57M8.75M543.00K
Free Cash Flow-1.15M-1.61M-2.79M-6.80M-16.18M-44.86M-25.59M-29.22M
FCF to OCF109.88%135.38%100.00%177.33%188.15%337.67%159.89%101.89%

Earnings

Report DateDec 31, 2021Apr 29, 2022Jun 30, 2022Nov 30, 2022Mar 1, 2023May 31, 2023Aug 30, 2023Nov 29, 2023Feb 28, 2024May 23, 2024Sep 12, 2024Nov 27, 2024May 28, 2025Sep 3, 2025Dec 3, 2025May 21, 2026Sep 10, 2026
EPS Estimate-----------------
EPS Actual-0.64-0.220.02-0.11-0.10-0.27-0.68-1.06-0.90-0.72-1.06-1.26-1.17-1.82-1.30-1.45-0.99
Surprise-----------------
Timing-After-hours-------After-hoursAfter-hours------

Key Statistics & Ratios

Market Cap120.10M
Enterprise Value104.94M
Trailing P/E0.00
Forward P/E0.00
Price / Sales500.43
Price / Book2.47
EPS-4.98
Book Value7.85
Revenue (TTM)240.00K
Gross Profit (TTM)-6.25M
EBITDA-19.20M
Profit Margin0.00%
Operating Margin-2313.33%
Return on Equity-46.98%
Return on Assets-18.57%
Shares Outstanding5.92M
Shares Float3.83M
Beta0.82
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%